2015
The Center for Genetic Engineering and Biotechnology (CIGB) registers the therapeutic recombinant vaccine HeberNasvac®, for nasal and parenteral administration, against chronic infection by the hepatitis B virus and the prevention of its possible consequences, which induces a strong immune response, an excellent safety profile, with very few and slight adverse reactions.